437 related articles for article (PubMed ID: 24711047)
41. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
Carroll CB; Webb D; Stevens KN; Vickery J; Eyre V; Ball S; Wyse R; Webber M; Foggo A; Zajicek J; Whone A; Creanor S
BMJ Open; 2019 Oct; 9(10):e029740. PubMed ID: 31594876
[TBL] [Abstract][Full Text] [Related]
42. Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease.
Chen T; Mirzadeh Z; Chapple KM; Lambert M; Shill HA; Moguel-Cobos G; Tröster AI; Dhall R; Ponce FA
J Neurosurg; 2018 Mar; 130(1):109-120. PubMed ID: 29547091
[TBL] [Abstract][Full Text] [Related]
43. Clinical Progression of Parkinson's Disease: Insights from the NINDS Common Data Elements.
Lewis MM; Harkins E; Lee EY; Stetter C; Snyder B; Corson T; Du G; Kong L; Huang X
J Parkinsons Dis; 2020; 10(3):1075-1085. PubMed ID: 32538866
[TBL] [Abstract][Full Text] [Related]
44. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
[TBL] [Abstract][Full Text] [Related]
45. Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
van den Heuvel L; Evers LJW; Meinders MJ; Post B; Stiggelbout AM; Heskes TM; Bloem BR; Krijthe JH
Mov Disord; 2021 Feb; 36(2):407-414. PubMed ID: 33107639
[TBL] [Abstract][Full Text] [Related]
46. Longitudinal metric properties of disability rating scales for Parkinson's disease.
Martinez-Martin P; Prieto L; Forjaz MJ
Value Health; 2006; 9(6):386-93. PubMed ID: 17076869
[TBL] [Abstract][Full Text] [Related]
47. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
48. Fatigue in levodopa-naive subjects with Parkinson disease.
Schifitto G; Friedman JH; Oakes D; Shulman L; Comella CL; Marek K; Fahn S;
Neurology; 2008 Aug; 71(7):481-5. PubMed ID: 18695158
[TBL] [Abstract][Full Text] [Related]
49. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
Schneider JS; Elm JJ; Parashos SA; Ravina BM; Galpern WR;
Parkinsonism Relat Disord; 2010 Sep; 16(8):507-12. PubMed ID: 20598621
[TBL] [Abstract][Full Text] [Related]
50. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease.
Suzuki M; Yoshioka M; Hashimoto M; Murakami M; Noya M; Takahashi D; Urashima M
Am J Clin Nutr; 2013 May; 97(5):1004-13. PubMed ID: 23485413
[TBL] [Abstract][Full Text] [Related]
51. Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Zhang ZX; Shang HF; Hu X; Chen S; Zhao Z; Du X; Surmann E; Bauer L; Asgharnejad M
Parkinsonism Relat Disord; 2016 Jul; 28():49-55. PubMed ID: 27172830
[TBL] [Abstract][Full Text] [Related]
52. A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.
Yoritaka A; Abe T; Ohtsuka C; Maeda T; Hirayama M; Watanabe H; Saiki H; Oyama G; Fukae J; Shimo Y; Hatano T; Kawajiri S; Okuma Y; Machida Y; Miwa H; Suzuki C; Kazama A; Tomiyama M; Kihara T; Hirasawa M; Shimura H; Hattori N
BMC Neurol; 2016 May; 16():66. PubMed ID: 27176725
[TBL] [Abstract][Full Text] [Related]
53. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Verschuur CVM; Suwijn SR; Boel JA; Post B; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Munts AG; Deuschl G; Lang AE; Dijkgraaf MGW; de Haan RJ; de Bie RMA;
N Engl J Med; 2019 Jan; 380(4):315-324. PubMed ID: 30673543
[TBL] [Abstract][Full Text] [Related]
54. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
Timmermann L; Oehlwein C; Ransmayr G; Fröhlich H; Will E; Schroeder H; Lauterbach T; Bauer L; Kassubek J
Postgrad Med; 2017 Jan; 129(1):46-54. PubMed ID: 27883297
[TBL] [Abstract][Full Text] [Related]
55. Barthel Index and modified Rankin Scale: Psychometric properties during medication phases in idiopathic Parkinson disease.
Taghizadeh G; Martinez-Martin P; Meimandi M; Habibi SAH; Jamali S; Dehmiyani A; Rostami S; Mahmuodi A; Mehdizadeh M; Fereshtehnejad SM
Ann Phys Rehabil Med; 2020 Nov; 63(6):500-504. PubMed ID: 31816448
[TBL] [Abstract][Full Text] [Related]
56. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort.
Chou KL; Elm JJ; Wielinski CL; Simon DK; Aminoff MJ; Christine CW; Liang GS; Hauser RA; Sudarsky L; Umeh CC; Voss T; Juncos J; Fang JY; Boyd JT; Bodis-Wollner I; Mari Z; Morgan JC; Wills AM; Lee SL; Parashos SA;
J Neurol Sci; 2017 Jun; 377():137-143. PubMed ID: 28477684
[TBL] [Abstract][Full Text] [Related]
57. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.
NINDS NET-PD Investigators
Neurology; 2007 Jan; 68(1):20-8. PubMed ID: 17200487
[TBL] [Abstract][Full Text] [Related]
58. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
Rascol O; Poewe W; Lees A; Aristin M; Salin L; Juhel N; Waldhauser L; Schindler T;
Arch Neurol; 2008 May; 65(5):577-83. PubMed ID: 18474731
[TBL] [Abstract][Full Text] [Related]
59. Trial of Deferiprone in Parkinson's Disease.
Devos D; Labreuche J; Rascol O; Corvol JC; Duhamel A; Guyon Delannoy P; Poewe W; Compta Y; Pavese N; Růžička E; Dušek P; Post B; Bloem BR; Berg D; Maetzler W; Otto M; Habert MO; Lehericy S; Ferreira J; Dodel R; Tranchant C; Eusebio A; Thobois S; Marques AR; Meissner WG; Ory-Magne F; Walter U; de Bie RMA; Gago M; Vilas D; Kulisevsky J; Januario C; Coelho MVS; Behnke S; Worth P; Seppi K; Ouk T; Potey C; Leclercq C; Viard R; Kuchcinski G; Lopes R; Pruvo JP; Pigny P; Garçon G; Simonin O; Carpentier J; Rolland AS; Nyholm D; Scherfler C; Mangin JF; Chupin M; Bordet R; Dexter DT; Fradette C; Spino M; Tricta F; Ayton S; Bush AI; Devedjian JC; Duce JA; Cabantchik I; Defebvre L; Deplanque D; Moreau C;
N Engl J Med; 2022 Dec; 387(22):2045-2055. PubMed ID: 36449420
[TBL] [Abstract][Full Text] [Related]
60. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.
Hauser RA; Li R; Pérez A; Ren X; Weintraub D; Elm J; Goudreau JL; Morgan JC; Fang JY; Aminoff MJ; Christine CW; Dhall R; Umeh CC; Boyd JT; Stover N; Leehey M; Zweig RM; Nicholas AP; Bodis-Wollner I; Willis A; Kieburtz K; Tilley BC;
J Parkinsons Dis; 2017; 7(1):117-127. PubMed ID: 27911341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
